On 28 April 2016, orphan designation (EU/3/16/1643) was granted by the European Commission to Cytori Ltd, United Kingdom, for autologous stromal vascular cell fraction from adipose tissue for the treatment of systemic sclerosis.
The sponsorship was transferred to Clinical Network Services (NL) B.V., Netherlanks, in March 2019.
In August 2020, Clinical Network Services (NL) B.V. changed name to Scendea (NL) B.V.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in August 2020 on request of the Sponsor.
In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.
Autologous stromal vascular cell fraction from adipose tissue
|Disease / condition||
Treatment of systemic sclerosis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.